ANTARES PHARMA INC's ticker is ATRS and the CUSIP is 036642106.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $8,281 | -16.5% | 2,275 | 0.0% | 0.00% | – |
| Q2 2021 | $9,919 | +6.1% | 2,275 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $9,350 | +3.0% | 2,275 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $9,077 | +47.8% | 2,275 | 0.0% | 0.00% | – |
| Q3 2020 | $6,143 | -1.8% | 2,275 | 0.0% | 0.00% | – |
| Q2 2020 | $6,256 | +16.5% | 2,275 | 0.0% | 0.00% | -100.0% |
| Q1 2020 | $5,369 | -49.8% | 2,275 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $10,693 | +40.5% | 2,275 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $7,610 | +1.7% | 2,275 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $7,485 | +8.6% | 2,275 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $6,893 | +11.4% | 2,275 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $6,188 | -19.0% | 2,275 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $7,644 | +30.2% | 2,275 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $5,870 | +17.3% | 2,275 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $5,005 | +10.6% | 2,275 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $4,527 | -38.6% | 2,275 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $7,371 | – | 2,275 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JW Asset Management, LLC | 1,671,956 | $5,384,000 | 3.43% |
| ARMISTICE CAPITAL, LLC | 5,700,000 | $18,354,000 | 2.34% |
| Rubric Capital Management LP | 3,188,600 | $10,267,000 | 2.12% |
| Broadfin Capital, LLC | 4,803,528 | $15,467,000 | 1.88% |
| THOMPSON DAVIS & CO., INC. | 192,734 | $621,000 | 1.00% |
| Asymmetry Capital Management, L.P. | 199,655 | $643,000 | 0.76% |
| Perceptive Advisors | 4,267,253 | $13,741,000 | 0.69% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 946,987 | $3,049,000 | 0.21% |
| Brown Advisory Securities, LLC | 275,000 | $886,000 | 0.20% |
| EAM Investors, LLC | 251,619 | $810,000 | 0.13% |